Seminars in Oncology Nursing
Volume 23 , Pages S23-S30 , November 2007

Managing Treatment Side Effects in Advanced Breast Cancer

  • Susan Moore

      Affiliations

    • Corresponding Author InformationAddress correspondence to Susan Moore, RN, MSN, ANP, AOCN®, CancerExpertise, 5437 W Warwick Ave, Chicago, IL 60641-3228

References 

  1. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932–2947
  2. Bender CM, McDaniel RW, Murphy-Ende K, et al. Chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs. 2002;6:94–102
  3. Marse H, Van Cutsem E, Grothey A, et al. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs. 2004;8(suppl 1):S16–S30
  4. Engelking C. Diarrhea. In:  Yarbro CH,  Frogge MH,  Goodman M editor. Cancer symptom management. Ed 3. Boston, MA: Jones and Bartlett; 2004;p. 528–550
  5. Benson AB, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22:2918–2926
  6. Saltz LB. Understanding and managing chemotherapy-induced diarrhea. J Support Oncol. 2003;1:35–46
  7. Tykerb. [package insert] Research Triangle Park, NC: GlaxoSmithKline; 2007;
  8. Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist. 2007;12:756–765
  9. Davison D. Oral mucositis. Clin J Oncol Nurs. 2006;10:283–284
  10. Oncology Nursing Society. Measuring oncology nursing-sensitive patient outcomes: evidence-based summary. Available at: http://onsopcontent.ons.org/toolkits/evidence/Clinical/pdf/MucositisSummary.pdf (accessed Septenber 28, 2007).
  11. Oncology Nursing Society. PEP Resource Vol II: Mucositis. Available at: http://www.ons.org/outcomes/volume2/mucositis.shtml (accessed September 28, 2007).
  12. Eilers J, Million R. Prevention and management of oral mucositis in patients with cancer. Semin Oncol Nurs. 2007;23:201–212
  13. Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100(suppl 9):2026–2046
  14. Wilkes GM, Doyle D. Palmar-plantar erythrodysesthesia. Clin J Oncol Nurs. 2005;9:103–106
  15. Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs. 2004;8(suppl 1):S31–S40
  16. Pike K. Hand-foot syndrome. Oncol Nurs Forum. 2001;28:1519–1520
  17. Marse H, Van Cutsem E, Grothey A, et al. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs. 2004;8(suppl 1):S16–S30
  18. Dick S, Crawford G. Managing cutaneous side effects of epidermal growth factor receptor (HER1/EGFR) inhibitors. Community Oncol. 2005;2:492–496
  19. Perez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005;10:345–356
  20. Morse L, Calarese P. EGFR-targeted therapy and related skin toxicity. Semin Oncol Nurs. 2006;22:152–162
  21. Lacouture ME, Basti S, Patel J, et al. The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol. 2006;4:236–238
  22. Sipples R. Common side effects of anti-EGFR therapy: acneform rash. Semin Oncol Nurs. 2006;22(suppl 1):28–34
  23. Fish-Steagall A, Searcy P, Sipples R. Clinical experience with anti-EGFR therapy. Semin Oncol Nurs. 2006;22(suppl 1):10–19
  24. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425–1433
  25. DeWitt CA, Siroy AE, Stone SP. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol. 2007;56:500–505
  26. Burris HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005;23:5305–5313
  27. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6:491–500
  28. Montagut C, Grau JJ, Grimalt R, et al. Abnormal hair growth in a patient with head and neck cancer treated with the anti-epidermal growth factor receptor monoclonal antibody cetuximab. J Clin Oncol. 2005;23:5273–5275
  29. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol. 2005;23:5235–5246
  30. Herceptin package insert. South San Francisco, CA: Genentech, Inc.; 2006;
  31. Perez EA, Byrne JA, Hammond IW, et al. Results of an analysis of cardiac function in 2,812 patients treated with lapatinib. J Clin Oncol. 2006;24(suppl 18S):583
  32. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820–7826

 The development of this article was based on a presentation given by S. Moore at the 2006 Oncology Nursing Society's 7th Annual Institutes of Learning; the author received an honorarium through an educational grant from GlaxoSmithKline.

 Ms Moore has served as a member of the Speaker's Bureau for Roche Laboratories, Genentech Inc., and GlaxoSmithKline.

PII: S0749-2081(07)00092-7

doi: 10.1016/j.soncn.2007.10.005

Seminars in Oncology Nursing
Volume 23 , Pages S23-S30 , November 2007

Article Tools

* Image Usage & Resolution